Enhancing immunogenic responses through CDK4/6 and HIF2α inhibition in Merkel cell carcinoma
Approximately 50% of Merkel cell carcinoma (MCC) patients facing this highly aggressive skin cancer initially respond positively to PD-1-based immunotherapy. Nevertheless, the recurrence of MCC post-immunotherapy emphasizes the pressing need for more effective treatments. Recent research has highlig...
Main Authors: | Jung Hyun Lee, Justin Daho Lee, Kelly Paulson, Valentin Voillet, Andre Berndt, Candice Church, Kristina Lachance, Song Y. Park, Naomi K. Yamamoto, Elizabeth A. Cromwell, Raphael Gottardo, Aude G. Chapuis, Paul Nghiem |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023107298 |
Similar Items
-
CDK1/2/5 blockade: killing two birds with one stone
by: Jiao Liu, et al.
Published: (2021-01-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01) -
The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
by: Emily Jiggens, et al.
Published: (2021-10-01) -
CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01) -
Identifying Cancers Impacted by CDK8/19
by: Igor B. Roninson, et al.
Published: (2019-08-01)